daunorubicin has been researched along with Atypical Chronic Myeloid Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eom, HS; Joo, YD; Jung, CW; Kim, DY; Kim, H; Kim, I; Kim, MK; Kim, SH; Kim, SJ; Lee, GW; Lee, JH; Lee, JJ; Lee, KH; Lee, SM; Lee, WS; Moon, JH; Mun, YC; Ryoo, HM; Shin, HJ; Sohn, SK; Won, JH; Yoon, SS | 1 |
| Boissel, N; Cluzeau, T; Devillier, R; Dombret, H; Kiladjian, JJ; Lengline, E; Raffoux, E; Rey, J; Robin, M; Ronchetti, AM; Sebert, M; Vey, N | 1 |
1 trial(s) available for daunorubicin and Atypical Chronic Myeloid Leukemia
| Article | Year |
|---|---|
Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System; Consolidation Chemotherapy; Cranial Irradiation; Daunorubicin; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemic Infiltration; Maintenance Chemotherapy; Male; Middle Aged; Prednisolone; Recurrence; Remission Induction; Survival Rate; Treatment Outcome; Vincristine; Young Adult | 2013 |
1 other study(ies) available for daunorubicin and Atypical Chronic Myeloid Leukemia
| Article | Year |
|---|---|
Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Feasibility Studies; Female; Humans; Idarubicin; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Nitriles; Pyrazoles; Pyrimidines; Treatment Outcome | 2016 |